News

April 2, 2018 - ViaCyte to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day in New York City Read More

April 2, 2018 - DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial Read More

April 1, 2018 - ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications Read More

January 24, 2018 - Research Collaboration between the San Francisco VA, UCSF and CalciMedica, Inc. to Present Results on CRAC Channel Inhibitors in a Stroke Model at International Conference Read More

January 19, 2018 - ViaCyte to Present at Three Upcoming Healthcare Events Read More

January 8, 2018 - Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive Officer Read More

January 5, 2018 - ViaCyte Announces First Patients Implanted in Cohort 2 with Potentially Efficacious Dose of PEC-Direct Islet Cell Replacement Therapy Read More

December 15, 2017 - CIRM Grants ViaCyte $1.4M to Create Immune-Evasive Pluripotent Stem Cell Lines Read More

December 6, 2017 - ViaCyte Selected as a Winner of CONNECT’s 30th Annual Most Innovative New Product Awards Read More

November 17, 2017 - Diazon Pharmaceutical’s anti-cancer agent DZ-2384 mechanism for high activity and low neurotoxicity published by McGill researchers in Science Translational Medicine Read More